Location History:
- Talence, FR (2013)
- Toulouse Cedex, FR (2015)
Company Filing History:
2 out of 1,746 
1 out of 213 
Years Active: 2013-2015
Title: Alexandre Dubrac: Innovator in Anti-Angiogenic Research
Introduction
Alexandre Dubrac is a notable inventor based in Toulouse Cedex, France. He has made significant contributions to the field of anti-angiogenic research, holding 2 patents that focus on innovative polypeptides and neutralizing antibodies.
Latest Patents
One of his latest patents involves mutants of PF4 polypeptides that exhibit an increased anti-angiogenic activity. This invention pertains to PF4 muteins which comprise a substitution at position 67, such as a L67H substitution, compared to the sequence of the wild-type PF4 protein. These PF4 muteins demonstrate an increased anti-angiogenic activity and a reduced affinity for proteoglycans compared to the wild-type PF4 protein. Another significant patent relates to neutralizing antibodies and fragments directed against Platelet Factor-4 variant 1 (PF4V1). This invention focuses on their use for treating pathologies that require the induction of angiogenesis or diseases associated with pathological angiogenesis.
Career Highlights
Throughout his career, Alexandre Dubrac has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and the Université de Bordeaux. His work has been pivotal in advancing the understanding of angiogenesis and its implications in various medical conditions.
Collaborations
He has collaborated with notable colleagues, including Andreas Bikfalvi and Herve Prats, contributing to a rich exchange of ideas and research in his field.
Conclusion
Alexandre Dubrac's innovative work in anti-angiogenic research highlights his role as a significant inventor in the scientific community. His patents reflect a commitment to advancing medical science and improving treatment options for diseases related to angiogenesis.